Author/Authors :
Brzezińska-Wcisło, Ligia Chair and Department of Dermatology - School of Medicine - Medical University of Silesia, Katowice, Poland , Zbiciak-Nylec, Martyna Andrzej Mielęcki Silesian Independent Public Hospital, Katowice, Poland , Wcisło-Dziadecka, Dominika Department of Skin Structural Studies - Chair of Cosmetology - School of Pharmacy with Division of Laboratory Medicine in Sosnowiec - Medical University of Silesia in Katowice, Poland , Salwowska, Natalia Chair and Department of Dermatology - School of Medicine - Medical University of Silesia, Katowice, Poland
Abstract :
Treatment during pregnancy is problematic. The Food and Drug Administration established drug categories to help in the treatment process. First-generation antihistamines are considered safe but they have sedative properties. Second-generation antihistamines cause less adverse reactions but besides cetirizine and loratadine they belong to category C. All retinoids should be avoided during pregnancy due to the risk of fetal malformations. Antimalarial drugs should be considered based on the clinical data. Sulfones can be considered as safe for use during pregnancy only with proper monitoring. Prednisone is administered in pregnancy. Other glucocorticosteroids have a different safety profile. Cyclosporine A treatment should be reserved as rescue therapy in severe stages of the disease. Treatment during pregnancy should be precise when it comes to pregnant woman and safe for the fetus.
Keywords :
pregnancy , antihistamine , drug categories , retinoids , antimalarial drugs
